Esomeprazole Sodium Manufacturers Directly Provide High Content Raw Powder, 99% Quality Assurance, 25kg/ Barrel
The product description
Molecular weight: 367.41
Appearance: White to light yellow powder
Content: 99% or higher
The indications are edited
Gastroesophageal Reflux Disease (GERD)- Treatment of erosive reflux Esophagitis - Long-term maintenance therapy to prevent recurrence in cured patients with esophagitis - Symptom control of Gastroesophageal reflux disease (GERD) in combination with appropriate antimicrobial therapy to eradicate Helicobacter pylori, And - Heal duodenal ulcers associated with Helicobacter pylori infection - prevent the recurrence of peptic ulcers associated with helicobacter pylori.
Esomeprazole, the S-optical isomer of omeprazole, is the world's first isomer proton pump inhibitor (PPI), which reduces gastric acid secretion by specifically inhibiting gastric parietal cell proton pump. A large number of clinical trials and drug studies have proved that it maintains pH> in the stomach; The time of 4 is longer, the acid inhibition efficiency is higher, the efficacy is better than the previous two generations of PPI, the individual difference is small. As a new generation of PPI, it has been widely used in clinical treatment of many acid-related diseases.
Proton pump inhibitors (PPI) are the drug of choice for treating acid-related diseases such as peptic ulcer and gastroesophageal reflux disease. The commonly used PPI in clinic included omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole. Prilosec, the first PPI drug, has been recognized for its efficacy in treating acid-related disorders. Nexium, or Nexium, is the single isomer of omeprazole, the (S) -isomer. Because of its metabolic advantages, esomeprazole has higher bioavailability and more consistent pharmacokinetics than prilosec, resulting in more drugs reaching the proton pump and better acid inhibition effect than other PPI.
Although oral esomepazole can achieve good clinical results, in some patients, such as dysphagia, vomiting, acute upper gastrointestinal bleeding and patients recovering from major surgery, oral administration becomes an unfeasible route of administration, and intravenous administration becomes an inevitable choice. Therefore, Esomeprazole sodium for injection is suitable for patients who require PPI but cannot be administered orally.
Pharmacological Research editor reports
Esomeprazole, an S-isomer of omeprazole, reduces gastric acid secretion through a specific raking mechanism and acts as a specific inhibitor of proton pumps in parietal cells. Site and mechanism of action: Esomeprazole is a weak base, which is concentrated and transformed into the active form in the high-acid environment of acid secreting microtubules in parietal cells, thus inhibiting H+/k+-ATP (proton pump) in this site, and inhibiting both basic and stimulated gastric acid secretion.
The pharmacokinetics editor
Absorption and distribution The maximum blood concentration (Cmax) of esomeprazole (40 mg) was increased with the speed of intravenous infusion. However, the area under the blood concentration-time curve (AUC) was relatively constant (7.07-7.38 μmol/L) regardless of the infusion rate, suggesting that the bioavailability was consistent. Drug interaction For drugs whose absorption process is affected by gastric acid, the absorption of these drugs may be increased or decreased during Nexium treatment due to a decrease in gastric acid. When esomeprazole is used with CYP2C19-metabolized drugs (e.g., diazepam, citalopram, imipramine, clomipramine, phenytoin, etc.), plasma concentrations of these drugs may be elevated, requiring appropriate dose reduction.
The pharmacodynamics editor
Mechanism of action The action mechanism of Esomeprazole is the same as that of omeprazole, that is, under acidic conditions, the prototic, esomeprazole is transformed into a compound with inhibitory activity of H+/K+ -ATpase, which rapidly combines with the sulfhydryl group of cysteine on H+/K+ -ATPase to form disulfide bond, thus inactivating the enzyme. Specifically inhibited the activity of H+/K+ -ATPase in gastric parietal cells and inhibited gastric acid secretion. Acid inhibition ability Existing studies have shown that intravenous administration of esomeprazole has the same acid inhibition effect as oral esomeprazole during repeated administration. In addition, the same package of Esomeprazole sodium can be used for both intravenous and intravenous infusion. Both groups were given 40 mg esomeprazole intravenously (3 minutes) and intravenously (30 minutes) for 10 days with the same effect on gastric acid suppression.
Studies have shown that esomeprazole for injection can inhibit acid faster and more effectively than other PPI for injection. Dirk et al. gave a single dose of 40 mg esomeprazole or 40 mg pantoprazole intravenously to healthy volunteers, and then continuously monitored the pH in the stomach. The durations of 4 were 3.4 and 2.1 hours, and the 24-hour corresponding values were 11.8 and 7.2 hours, respectively. Wilder et al. showed that repeated intravenous administration of esomeprazole inhibited gastric acid faster and more effectively than pantoprazole at the same dose. Recent studies have also shown that intravenous esomeprazole inhibits basal and stimulated gastric acid secretion more quickly and completely than omeprazole at the same dose.
Clinical application of